Semaglutide, initially FDA-approved for diabetes, gained approval in 2021 for "chronic weight management" and is known for its appetite-suppressing effects.
Musk, who claims to rarely work out and enjoys indulging in treats like doughnuts, mentioned Wegovy's role in his physical condition on the social media app X (formerly Twitter).
Wegovy, Novo Nordisk's brand of semaglutide, can lead to a 15% to 20% body weight loss over 68 weeks, but it comes with a high price tag of up to $1,349 per month.
The drug is approved for weight loss in individuals with a BMI over 30 or over 25 with conditions like type 2 diabetes, contributing to its popularity among celebrities.
Celebrities like Amy Schumer and Chelsea Handler have also endorsed semaglutide, creating a cultural buzz around the drug, even making it a joke at the 2023 Oscars.
The FDA recommends semaglutide for weight loss in conjunction with a reduced-calorie diet and increased physical activity.
The drug's effectiveness is coupled with gastrointestinal side effects, including nausea and severe diarrhea, posing challenges for some users.
Semaglutide's popularity highlights the intersection of fame, fitness, and pharmaceuticals, shedding light on the evolving landscape of weight-loss solutions.